Akesis names John L. Capicchioni as new president

Thursday, May 31, 2012 12:34 PM

Akesis, a Lake Wylie, S.C.-based contract research firm specializing in phase II-IV clinical dermatology services and regulatory affairs consulting, has appointed John L. Capicchioni as its new president.

Capicchioni will be responsible for providing strategic leadership and managerial oversight of the company while driving growth and assuring quality, cost optimization and best business practices to pharmaceutical, device, generic, formulation development and biotechnology companies.

Capicchioni brings 22 years of global CRO experience to Akesis. He has held a broad range of executive leadership positions, overseeing global sales, project management, marketing and client services. He has served as senior vice president of business development for global early clinical and bioanalytical research at MDS Pharma Services (now Celerion), where he directed the pharmaceutical and generic segments. He has also held senior posts at Phoenix International Life Sciences. Capicchioni has also served on the board of directors of the Generic Pharmaceutical Association as the elected member for CROs.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs